---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-240127"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T14:24:48.745476+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Erasca reports 23% response rate in RAS/MAPK-altered non-CRC tumors; combo trial in H1 2023

## Summary
- 23% (6/26) of RAS/MAPK-altered non-CRC solid tumor patients responded to single-agent ERAS-007 or ERAS-601.
- 44% (4/9) of BRAF-driven non-CRC solid tumor patients responded (1 confirmed PR, 3 unconfirmed PRs).
- Favorable safety profiles with largely non-overlapping, manageable treatment-related adverse events.
- Company plans to initiate ERAS-007 + ERAS-601 (MAPKlamp) dose escalation trial in first half of 2023.
- Retrospective pooled analysis included HERKULES-1, FLAGSHP-1, and ASN007-101 trials with data cutoffs through July 2022.

## SEC filing metadata
- accession: 0001193125-22-240127
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312522240127/0001193125-22-240127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312522240127/d399259d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-240127
- JSON: https://secwatch.observer/filing/0001193125-22-240127.json
- Plain text: https://secwatch.observer/filing/0001193125-22-240127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.